Table 1.
Demographic characteristics, diagnoses, and treatments of the study participants
| Recurrence (+) n=19 |
Recurrence (-) n=51 |
All n=70 |
|
|---|---|---|---|
| Age - year, median (range) | 76 (33, 91) | 78 (32, 89) | 76 (32, 91) |
| Sex - male, n (%) | 11 (57.9) | 32 (62.8) | 43 (61.4) |
| Pathological diagnosis, n (%) | |||
| Dysplasia | 1 (5.3) | 7 (13.7) | 8 (11.4) |
| CIN | 7 (36.8) | 19 (37.3) | 26 (37.1) |
| SCC (TNM: T1) | 0 (0) | 5 (9.8) | 5 (7.1) |
| SCC (TNM: T2) | 9 (47.4) | 20 (39.2) | 29 (41.4) |
| SCC (TNM: T3) | 2 (10.5) | 0 (0) | 2 (2.9) |
| Lesion location, n (%) | |||
| Corneal limbus | |||
| < 1 quadrant | 5 (26.3) | 26 (51.0) | 31 (44.3) |
| < 2 quadrants | 4 (21.1) | 11 (21.6) | 15 (21.4) |
| < 3 quadrants | 3 (15.8) | 5 (9.8) | 8 (11.4) |
| All quadrants | 4 (21.1) | 1 (2.0) | 5 (7.1) |
| Palpebral conjunctiva | 1 (5.3) | 7 (13.7) | 8 (11.4) |
| In bulbar & palpebral conjunctiva | 2 (10.5) | 1 (2.0) | 3 (4.3) |
| Size - mm, median (range) | 7.0 (3.0, 17.0) | 10.0 (6.0, 20.0) | 8.0 (3.0, 20.0) |
| HPV16 - positive, n (%) | 2 (11.1) | 3 (8.1) | 5 (9.1) |
| Missing | 1 | 14 | 15 |
| Operation, n (%) | |||
| LT/KEP | 10 (52.6) | 12 (23.5) | 22 (31.4) |
| COMET | 1 (5.3) | 0 (0) | 1 (1.4) |
| CT | 0 (0) | 2 (3.9) | 2 (2.9) |
| AMT | 2 (10.5) | 11 (21.6) | 13 (18.6) |
| ET + AMT | 3 (15.8) | 6 (11.8) | 9 (12.9) |
| None | 3 (15.8) | 20 (39.2) | 23 (32.9) |
| MMC, n (%) | 15 (78.9) | 43 (84.3) | 58 (82.9) |
| 5-FU, n (%) | 2 (10.5) | 28 (54.9) | 30 (42.9) |
| IFN, n (%) | 2 (10.5) | 3 (5.9) | 5 (7.1) |
CIN, carcinoma in situ; SCC, squamous cell carcinoma; HPV16, human papillomavirus 16; LT, limbal transplantation; KEP, keratoepithelioplasty; COMET, cultivated oral mucosal epithelial transplantation; CT, auto-conjunctival transplantation; AMT, amniotic membrane transplantation; ET, epithelial transplantation; None, only excision of the tumor; MMC, (intraoperative) mitomycin-C; 5-FU, (postoperative) 5-fluorouracil; IFN, (postoperative) interferon-α-2b